Paris – (business wire)–Regulatory News:
Onseo SA (Euronext Growth Paris: ALONX), hereinafter “Onseo” or “companyA clinical-stage biotechnology company dedicated to developing innovative medicines that target tumor DNA damage response (DDR) mechanisms to combat rare or resistant cancers We are pleased to announce that the preparatory documents for the General Assembly are now available. February 6, 2023 at 2:00 pm at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris – France.
Shareholders are asked to consider, among other things, approval of the Board of Directors to proceed with capital reductions by reducing the par value of the shares, and proposals for reverse stock splits. of the shares that make up our share capital; These two potential manipulations represent purely arithmetic technical adjustments and do not affect the value of stock portfolios held by shareholders or the market capitalization of Onxeo.
A Notice of Meeting was published in BALO on December 28, 2022 and an Amendment Notice was published in BALO on January 16, 2023. General Assembly section.
Onseo (Euronext Growth Paris: ALONX) is a clinical stage developing innovative oncology drugs that target DNA-binding functions of tumors through a unique mechanism of action sought in the area of DNA damage response (DDR) is a biotechnology company. We focus on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept to value creation inflection points that appeal to potential partners.
Plato™ is Onxeo’s proprietary chemical platform of oligonucleotides that act as decoy agonists, generating new innovative compounds and expanding our product pipeline.
Reed DNAIt is the first compound from platON . Its decoy and agonist mechanism, which acts upstream of multiple DDR pathways, is associated with its ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors, as well as tumors such as radiochemotherapy. It offers unique anti-tumor properties, including strong synergy with DNA-damaging agents. AsiDNA is currently being investigated in combination with other therapies for difficult-to-treat solid tumors in the West.
OX425, The second compound in platON is a novel DDR decoy agonist with high anti-tumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. OX425 is currently in IND-ready preclinical development.
For more information, please visit: www.onxeo.com.
This communication contains, expressly or impliedly, certain forward-looking statements regarding Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors that may cause Onxeo’s actual results, financial position, performance or achievements to differ in the future. may differ materially from future results, performance or achievements expressed or implied by the forward-looking statements. Onxeo is providing this notice as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of the risks and uncertainties that could cause Onxeo’s actual results, financial condition, performance or performance to differ from those contained in the forward-looking statements, please consult the latest company registration documents or any Please refer to the risk factors listed in the document. Other periodic financial reports and other press releases are available free of charge on the websites of the Group (www.onxeo.com) and/or AMF (www.amf-france.org).